LianBio Increase (Decrease) in Accrued Liabilities
LianBio (LIANY) reported Increase (Decrease) in Accrued Liabilities of -$3.38 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2023-11-13
- LianBio increase (decrease) in accrued liabilities for the quarter ending 2023-09-30 was -$1.18M, a 250.32% decline year-over-year.
- LianBio increase (decrease) in accrued liabilities for the quarter ending 2023-06-30 was $1.08M, a 59.48% decline year-over-year.
- LianBio increase (decrease) in accrued liabilities for the quarter ending 2023-03-31 was -$3.28M, a 169.26% decline year-over-year.
- LianBio increase (decrease) in accrued liabilities for the quarter ending 2022-12-31 was $1.65M.
- LianBio increase (decrease) in accrued liabilities for fiscal 2022 was $9.84M, a 12.34% increase from fiscal 2021.
- LianBio increase (decrease) in accrued liabilities for fiscal 2021 was $8.76M, a 980.27% increase from fiscal 2020.
- LianBio increase (decrease) in accrued liabilities for fiscal 2020 was $811.00K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$93.00K derived: sum of 2 quarters · filed 2023-11-13 | -$3.38M 10-Q · filed 2023-11-13 | -$1.73M derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$2.20M 10-Q · filed 2023-08-14 | -$553.00K derived: sum of 3 quarters · filed 2023-08-14 | $230.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-03-31 | -$3.28M 10-Q · filed 2023-05-11 | -$1.64M derived: sum of 2 quarters · filed 2023-05-11 | -$854.00K derived: sum of 3 quarters · filed 2023-11-13 | $1.82M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-12-31 | $1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $2.43M derived: sum of 2 quarters · filed 2023-11-13 | $5.10M derived: sum of 3 quarters · filed 2023-11-13 | $9.84M 10-K · filed 2023-03-28 |
| 2022-09-30 | $783.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $3.46M derived: sum of 2 quarters · filed 2023-11-13 | $8.20M 10-Q · filed 2023-11-13 | $5.39M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $2.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $7.41M 10-Q · filed 2023-08-14 | $4.61M derived: sum of 3 quarters · filed 2023-08-14 | $8.00M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $4.74M 10-Q · filed 2023-05-11 | $1.93M derived: sum of 2 quarters · filed 2023-05-11 | $5.32M derived: sum of 3 quarters · filed 2023-05-11 | -$15.15M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $583.00K derived: sum of 2 quarters · filed 2023-03-28 | -$19.89M derived: sum of 3 quarters · filed 2023-03-28 | $8.76M 10-K · filed 2023-03-28 |
| 2021-09-30 | $3.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$17.09M derived: sum of 2 quarters · filed 2022-11-10 | $11.57M 10-Q · filed 2022-11-10 | $8.97M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$20.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $8.18M 10-Q · filed 2022-08-11 | $5.58M derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | $28.65M 10-Q · filed 2022-05-12 | $26.06M derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$2.60M derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-31 | $811.00K 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $3.41M 10-Q/A · filed 2022-01-10 |